E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with exudative AMD with focal vitreomacular adhesion |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10015902 |
E.1.2 | Term | Exudative senile macular degeneration of retina |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10051065 |
E.1.2 | Term | Vitreomacular traction syndrome |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10060823 |
E.1.2 | Term | Choroidal neovascularisation |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the safety and preliminary efficacy of intravitreal microplasmin in patients with exudative AMD with focal vitreomacular adhesion |
|
E.2.2 | Secondary objectives of the trial | |
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
-Male or female patients aged > 50 -Presence of focal vitreomacular adhesion with a central retinal thickness of at least 250 µm as measured by OCT. -Diagnosis of active primary or recurrent subfoveal CNV secondary to AMD, including those with predominantly classic, minimally classic or occult lesions with no classic component. -The total area of CNV (including both classic and occult components) encompassed within the lesion must be > 50% of the total lesion area -The total lesion area must be < 12 disc areas -Patients with visual acuity of 20/40 to 20/200 in the study eye -Written informed consent obtained from the patient prior to inclusion in the study
|
|
E.4 | Principal exclusion criteria |
-Evidence of complete macular PVD in the study eye on biomicroscopy, B-scan ultrasound or OCT prior to planned study drug injection -Patients with vitreous haemorrhage which precludes either of the following: visualization of the posterior pole by visual inspection OR adequate assessment of the macula by either OCT and/or fluorescein angiography in the study eye or other opacities precluding visualisation of the fundus. -Patients with history of rhegmatogenous retinal detachment or PVR in the study eye -Patients with high myopia (> 8D) or aphakia in the study eye -Patients who have had ocular surgery in the study eye in the prior three months -Patients who have had a vitrectomy in the study eye at any time. -Patients with uncontrolled glaucoma in the study eye (defined as intraocular pressure > 26 mm Hg in spite of treatment with anti-glaucoma medication) -Intravitreal injection of any drug or photodynamic therapy in the study eye in the previous 10 days or such planned treatment in the 10 days following study drug injection -Patients who are pregnant or of child-bearing potential not utilizing an acceptable form of contraception. Acceptable methods of birth control include intrauterine device, oral, implanted, or injected contraceptives, and barrier methods with spermicide. -Patients who, in the investigators view, will not complete all visits and investigations -Patients who have participated in an investigational drug study within the past 30 days -Patients who have previously participated in this trial
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Safety Endpoint:
-History/full ophthalmologic examination (including dilated biomicroscopy, ophthalmoscopy, OCT): baseline, post-injection days 7, 14 and 28 and post-injection months 3, 6 and 12. -Fundus Photography: baseline, day 28 and 12 months post-injection -Fluorescein angiography: baseline, day 28 and 12 months post-injection
Efficacy Primary endpoint -Proportion of patients with release of focal vitreomacular adhesion by day 28 as determined by masked Central Reading Center evaluation of imaging (OCT)
Efficacy Secondary endpoint: -Vitreomacular adhesion status and PVD status at visits other than day 28 post-injection visit (OCT and ultrasound) -Visual Acuity (ETDRS) -Central retinal/lesion thickness (OCT) -Membrane growth: evaluated by OCT (spectral domain where available) and fluorescein-angiography -Size of fluorescein leakage -Number of patients requiring additional therapy -Number of injections of anti-VEGF required -Initial fluid-free interval and anti-VEGF free interval -Time to 4th anti-VEGF injection -VFQ-25
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 12 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial is defined as the last visit of the last subject, unless the Safety Committee recommends premature termination of the trial as a result of safety concerns |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |